Kuros Biosciences AG
OTC:CSBTF

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
OTC:CSBTF
Watchlist
Price: 34.65 USD Market Closed
Market Cap: $1.3B

Net Margin

-6%
Current
Improving
by 32.2%
vs 3-y average of -38.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6%
=
Net Income
CHf-7.1m
/
Revenue
CHf118.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6%
=
Net Income
$-7.1m
/
Revenue
CHf118.4m

Peer Comparison

Country Company Market Cap Net
Margin
CH
Kuros Biosciences AG
SIX:KURN
995.2m CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.3B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 85% of companies in Switzerland
Percentile
15th
Based on 1 179 companies
15th percentile
-6%
Low
-57 027.8% — 1.3%
Typical Range
1.3% — 13.7%
High
13.7% — 3 663.7%
Distribution Statistics
Switzerland
Min -57 027.8%
30th Percentile 1.3%
Median 7.2%
70th Percentile 13.7%
Max 3 663.7%

Kuros Biosciences AG
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

CSBTF Intrinsic Value
50.42 USD
Undervaluation 31%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-6%
=
Net Income
CHf-7.1m
/
Revenue
CHf118.4m
What is Kuros Biosciences AG's current Net Margin?

The current Net Margin for Kuros Biosciences AG is -6%, which is above its 3-year median of -38.3%.

How has Net Margin changed over time?

Over the last 3 years, Kuros Biosciences AG’s Net Margin has increased from -73.5% to -6%. During this period, it reached a low of -81.1% on Dec 31, 2022 and a high of -5.7% on Dec 31, 2024.

Back to Top